Skip to content

Conventional vs Neurally Adjusted Ventilatory Assist in Difficult Weaning From Mechanical Ventilation

A Prospective, Randomized and Controlled Study Estimating the Neurally Adjusted Ventilatory Assist (NAVA) Versus the Pressure Support Ventilatory (PSV) in Difficult Weaning From Mechanical Ventilation

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02382861
Acronym
SENA
Enrollment
47
Registered
2015-03-09
Start date
2015-02-20
Completion date
2017-01-01
Last updated
2026-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Failure

Keywords

Neurally adjusted ventilatory assist, Weaning, Mechanical ventilation, Extubation

Brief summary

The NAVA, by its more physiological aspect and a better adaptation of the patient to the ventilator with a decrease of asynchronies patients-ventilators, could decrease the duration of weaning and so decrease the duration of invasive mechanical ventilation and the morbi-mortality. The objective of this study is to compare the neurally adjusted ventilatory assist versus the usual management of weaning from mechanical ventilation, in term of duration of weaning, at the patients in period of difficult weaning from the invasive mechanical ventilation.

Detailed description

\- Background: The NAVA is a new mode of ventilation which works from the continuous recording of the electromyogram of the diaphragm. In theory, the NAVA delivred a proportional and synchronous assistance, to respiratory efforts allowing a more adequate ventilatory support. However, no study estimates the NAVA in the weaning from mechanical ventilation. \- Purpose: The NAVA, by its more physiological aspect and a better adaptation of the patient to the ventilator with a decrease of asynchronies patients-ventilators, could decrease the duration of weaning and so decrease the duration of invasive mechanical ventilation and the morbi-mortality. The objective of this study is to compare the neurally adjusted ventilatory assist versus the usual management of weaning from mechanical ventilation, in term of duration of weaning, at the patients in period of difficult weaning from the invasive mechanical ventilation. \- Detailed description: Approximately 20 to 25 % of the patients under mechanical ventilation who have the general criteria of weaning will not pass a first SBT (Spontaneous Breathing Trial). At this moment, the management of the weaning ventilatoire are made with PSV. The NAVA is proportional assistance and depends on the intensity of the electric diaphragmatic signal (Edi). The respiratory effort of the patient is directly detected from the Edi signal. In theory, the NAVA is a proportional and synchronous respiratory. * After a first failure of a SBT, patients respecting the inclusion criteria and exlusion criteria described above are then included in the study and randomized in two groups (control group or NAVA group). * In the control group, the PSV is decreased of 2cmH2O daily or several times a day to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg. * In the NAVA group, the level of NAVA is daily adjusted to obtain Eadimax corresponding to 60 % of Eadimax of the patient during the SBT to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg. * Twice a day, the criteria of SBT are looked for. When they are present, a SBT is realized. If it is a success, the patient will be extube. If it is a failure, the patient will be reventilated in PSV or NAVA according to their group. A non-invasive ventilation preventive or of "rescue" can be administered post-extubation according to criteria. The reintubated criteria are also defined.

Interventions

In the NAVA group, the level of NAVA is daily adjusted to obtain Eadimax corresponding to 60 % of Eadimax of the patient during the SBT to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.

In the control group, the PSV is decreased of 2cmH2O daily or several times a day to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \>18 years * Under mechanical ventilation \> 48 hours * A first failure of a SBT * Plateau pressure 30cmH2O with tidal volume 8ml / kg * SpO2 ≥ in 90 % with a FiO2 ≥ 50 %, or PaO2 / FiO2 \> 150mmHg * Positive expiratory pressure 8cmH2O * No more of one mg/hour of noradrenaline or adrenalin * Temperature \>36 and \<39°C. * Stable neurological state (Glasgow scale \> 4) without sedation (or very low sedation). * Consent, dated and signed by the patient or his representative.

Exclusion criteria

* Contraindications to the NAVA (recent high digestive suture or oesophageal varices bleeding \< 4 days). * Pregnant woman. * Age \<18 years. * Tracheotomy. * Cardiac arrest with a reserved neurological prognostic. * Therapeutic limitation.

Design outcomes

Primary

MeasureTime frameDescription
Duration of weaning from the mechanical invasive ventilation.48 hours after the extubationThis duration is defined by the period between the first failure of the spontaneous breathing trial (SBT) and 48 hours after the extubation.

Secondary

MeasureTime frame
Duration between the inclusion and the success of the SBT28th day
Duration of invasive mechanical ventilation28th day
Rate of failure of SBT28th day
Rate of success of SBT28th day
Rate of ventilator-associated pneumonia28th day
Length of intensive care unit stay28th day
Duration of hospitalization28th day

Countries

France

Contacts

STUDY_CHAIRPaul PEREZ, Doctor

University Hospital, Bordeaux

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 23, 2026